Gene therapy trial for diabetic macular edema
Part of Eyes & vision clinical trials.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 1 or type 2 diabetes with swelling in the center of the retina (DME).
- Your retinal thickness is at least 300 micrometers in the study eye.
- Your vision in the study eye is between 19 and 73 letters on an eye chart (roughly 20/400 to 20/40).
- You have had anti-VEGF injections in the past year and they helped somewhat.
- You have not had certain other eye treatments recently (like laser, steroid implants, or gene therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
This trial tests a gene therapy for diabetic macular edema (DME), a condition where fluid builds up in the central part of the eye's retina. It aims to improve vision and reduce the need for frequent eye injections.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This trial tests a new gene therapy called LX109 for wet age-related macular degeneration (nAMD). It is for patients who still need regular anti-VEGF injections, and the treatment aims to reduce how often you need those injections.
This early-stage (Phase 1) study tests a new gene therapy to improve vision for adults with diabetic macular edema. It mainly looks at whether the treatment can be safely given and may help your vision over time.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.